RT Journal Article
SR Electronic
T1 COVID-19 pandemic re-shaped the global dispersal of seasonal influenza viruses
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.12.20.23300299
DO 10.1101/2023.12.20.23300299
A1 Chen, Zhiyuan
A1 Tsui, Joseph L.-H.
A1 Gutierrez, Bernardo
A1 Moreno, Simon Busch
A1 Plessis, Louis du
A1 Deng, Xiaowei
A1 Cai, Jun
A1 Bajaj, Sumali
A1 Suchard, Marc A.
A1 Pybus, Oliver G.
A1 Lemey, Philippe
A1 Kraemer, Moritz U. G.
A1 Yu, Hongjie
YR 2023
UL http://medrxiv.org/content/early/2023/12/24/2023.12.20.23300299.abstract
AB Understanding how the global dispersal patterns of seasonal influenza viruses were perturbed during and after the COVID-19 pandemic is needed to inform influenza intervention and vaccination strategies in the post-pandemic period. Although global human mobility has been identified as a key driver of influenza dispersal1, alongside climatic and evolutionary factors2,3, the impact of international travel restrictions on global influenza transmission and recovery remains unknown. Here we combine molecular, epidemiological, climatic, and international travel data within a phylodynamic framework to show that, despite human mobility remaining the principal driver of global influenza virus dissemination, the pandemic’s onset led to a shift in the international population structure and migration network of seasonal influenza lineages. We find that South Asia and Africa played important roles as exporters and phylogenetic trunk locations of influenza in 2020 and 2021, and we highlight the association between population movement, antigenic drift and persistence during the intensive non-pharmaceutical interventions (NPIs) phase. The influenza B/Yamagata lineage disappeared in a context of reduced relative genetic diversity, moderate lineage turnover, and lower positive selection pressure. Our results demonstrate that mobility perturbations reshaped the global dispersal dynamics of influenza viruses, with potential implications for vaccine design and genomic surveillance programmes. As the risk of future pandemics persists, our study provides an opportunity to assess the impact of NPIs during the pandemic on respiratory infectious diseases beyond the interplay between SARS-CoV-2 and influenza viruses.Competing Interest StatementH.Y. received research funding from Sanofi Pasteur, GlaxoSmithKline, Yichang HEC Changjiang, Shanghai Roche Pharmaceutical Company, and SINOVAC Biotech Ltd. None of these funds are related to this work. All other authors declare no competing interests.Funding StatementH.Y. acknowledges financial support from the Key Program of the National Natural Science Foundation of China (No. 82130093) and the General Program of the National Natural Science Foundation of China (No. 82073613). M.U.G.K. acknowledges funding from The Rockefeller Foundation, Google.org, the Oxford Martin School Pandemic Genomics programme (also O.G.P.), European Union Horizon 2020 project MOOD (#874850), The John Fell Fund, a Branco Weiss Fellowship and Wellcome Trust grants 225288/Z/22/Z and 226052/Z/22/Z. P.L. acknowledges support from the European Research Council (grant agreement no. 725422 - ReservoirDOCS). J.C. acknowledges financial support from the Young Scientists Fund of the National Natural Science Foundation of China (No. 82304199).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Genetic sequences used were available in NCBI (https://www.ncbi.nlm.nih.gov/labs/virus/vssi/#/) and GISAID (https://www.gisaid.org/).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe codes and accession IDs of sequences used to run the phylogenetic analysis are available here: https://github.com/zychenfd/global_influenza_project. https://github.com/zychenfd/global_influenza_project